/

Ocean Biomedical, Inc.

OCEA US

OCEA USOcean Biomedical, Inc.

United States Composite

1.51

USD

+0.11

(+7.50%)

-3.25EPS Dil.

-0.46P/E

51.19MMarket Cap

Held by Insiders

73.18%

Held by Institutions

13.72%

Short % of Float

8.69%

YTD Yield

-76.56%

Capital Structure

FRC

•

in mil. unless spec.

Dec'22

Mar'23

Jun'23

ST Debt

LT Borrowings

- -

LT Finance Leases

- -

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

380

224

204

Working Capital

FRC

•

in mil. unless spec.

Dec'22

Mar'23

Jun'23

Total Current Assets

Cash, Cash Equivalents & STI

Accounts Receivable, Net

- -

Inventories

- -

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

- -

Net Income, GAAP

-NaN%

98.39%

Free Cash Flow

- -

Total Cash Common Dividend

- -

Total Equity

-NaN%

-0.95%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-1.35

-0.26

-0.24

-0.40

-3.09

2022

- -

-0.27

-0.36

- -

-0.03

2023

-2.72

-0.49

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Ms. Elizabeth Ng M.B.A.
Sector: Healthcare
Industry: Biotechnology
Address: Room 325, 55 Claverick Street Providence RI United States 02903
Website: www.oceanbiomedical.com
Business: Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP. The company is based in Providence, Rhode Island. Ocean Biomedical, Inc. operates as a subsidiary of Poseidon Bio, LLC.

Company News

Yahoo
a month ago
Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL

Company Description

CEO: Ms. Elizabeth Ng M.B.A.
Sector: Healthcare
Industry: Biotechnology
Address: Room 325, 55 Claverick Street Providence RI United States 02903
Website: www.oceanbiomedical.com
Business: Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP. The company is based in Providence, Rhode Island. Ocean Biomedical, Inc. operates as a subsidiary of Poseidon Bio, LLC.